ZW191 for Advanced Cancers
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment called ZW191 to determine its safety and effectiveness for people with advanced cancers. The focus is on difficult-to-treat cancers such as ovarian, endometrial, and non-small cell lung cancers. The trial seeks participants with a confirmed diagnosis of these advanced cancers that cannot be surgically removed or have metastasized. Ideal candidates may have tried other treatments without success and have no other serious health issues that could affect the study. As a Phase 1 trial, this research aims to understand how the treatment works in people, offering participants the opportunity to be among the first to receive it.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. However, if you are on treatments for severe infections or have received certain cancer treatments before, it might affect your eligibility.
Is there any evidence suggesting that ZW191 is likely to be safe for humans?
Research has shown that ZW191 is safe for people with advanced solid tumors. In earlier studies, patients received doses up to 11.2 mg/kg without major problems. Most patients continued the treatment without significant issues, suggesting that ZW191 is generally well-tolerated in humans. While this is early evidence of safety, it encourages those considering participation in clinical trials for this treatment.12345
Why do researchers think this study treatment might be promising?
ZW191 is unique because it targets advanced cancers in a new way. Unlike traditional chemotherapy, which attacks all rapidly dividing cells, ZW191 is designed to specifically target cancer cells, potentially reducing side effects and improving effectiveness. Researchers are excited about ZW191's novel mechanism of action, which aims to disrupt cancer cell growth more precisely, offering hope for patients with limited treatment options.
What evidence suggests that ZW191 might be an effective treatment for advanced cancers?
Research has shown that ZW191, the investigational treatment in this trial, may help treat advanced cancers. Early results indicate that 44% of patients with these cancers responded to the treatment. Specifically, patients with gynecological cancers, such as ovarian and endometrial cancers, showed a 64% response rate when given higher doses. These findings suggest that ZW191 could be effective for these cancers, with positive responses even at lower doses. The treatment appears safe and well-tolerated, which is also promising.13678
Who Is on the Research Team?
Akira Kojima, MD
Principal Investigator
Zymeworks BC Inc.
Are You a Good Fit for This Trial?
This trial is for people with advanced cancers like ovarian, endometrial, and non-small cell lung cancer. Participants must have a confirmed diagnosis of these cancers that are advanced or metastatic, measurable by certain criteria (RECIST v1.1), good heart function (LVEF ≥ 50%), and be in fairly good health overall (ECOG score of 0 or 1).Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment Part 1
Evaluation of safety and tolerability of ZW191
Treatment Part 2
Further evaluation of safety and exploration of anti-tumor activity of ZW191
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- ZW191
Find a Clinic Near You
Who Is Running the Clinical Trial?
Zymeworks BC Inc.
Lead Sponsor